Duncan McKechnie

Duncan McKechnie is Executive Vice President and Chief Commercial Officer at Vertex Pharmaceuticals. After joining the company in 2013, he progressed through commercial leadership roles spanning global strategy, North America operations, market access and pricing before assuming responsibility for the company's worldwide commercial organization. His career reflects a consistent focus on expanding patient access while preparing commercial teams for new therapeutic areas.

Turning Scientific Progress into Patient Access

Bringing a new therapy to market takes more than scientific success. It also requires careful work on reimbursement, local regulations and patient access before patients can benefit.

McKechnie's role sits at that intersection. He oversees Vertex's global commercial organization, guiding the teams responsible for marketing, sales, market access and patient support in markets where the company's medicines are approved. His earlier leadership of Global Pricing and Market Access, followed by responsibility for Global Health Economics, provides continuity between clinical value, payer expectations and commercial execution.

That breadth has become increasingly important as Vertex expands beyond its long-established cystic fibrosis portfolio into additional disease areas. Each expansion requires commercial strategies suited to different patient populations, healthcare systems and reimbursement models instead of relying on a single playbook.

Preparing Organizations Before Markets Change

Commercial organizations usually receive attention during product launches, although much of their work begins years earlier. Market access planning, evidence generation and engagement with healthcare stakeholders all influence whether a launch gains traction once regulatory approval arrives.

Much of McKechnie's work has focused on laying the groundwork before new therapies reach patients. Before becoming Chief Commercial Officer, he led North America Commercial and supported launches that expanded Vertex's portfolio. He later took on broader responsibilities that included pricing, reimbursement and health economics.

Earlier roles at Novartis also exposed him to global commercial leadership in different therapeutic categories and healthcare systems. Experience gained in the United Kingdom, Switzerland and the United States now supports decisions that require balancing global consistency with local market realities.

Experience like this is more important as biotechnology companies expand into specialized therapies. Scientific progress alone does not guarantee wide adoption. Commercial teams also need to show the value of new treatments to healthcare providers, work with payers and help remove barriers that can limit patient access.

Keeping Commercial Teams Aligned with Long-term Growth

Leading a global commercial organization requires attention to continuity as much as expansion. New therapeutic areas bring unfamiliar customer groups, different treatment pathways and evolving evidence requirements that place fresh demands on commercial teams.

McKechnie stepped into the Chief Commercial Officer role after holding several senior commercial positions within Vertex. Continuity can be valuable when organizations broaden their portfolios because institutional knowledge remains connected to new commercial priorities.

His responsibilities now cover markets where approved medicines are available, requiring coordination between regional teams while maintaining a consistent approach to patient support and market access. The work calls for disciplined execution, thoughtful resource allocation and a clear understanding of how commercial decisions influence patient access over time.

Scientific breakthroughs are only valuable if patients can benefit from them. McKechnie's career reflects that responsibility through continuous attention to market access, commercial readiness and global execution. Those priorities remain just as relevant as biotechnology companies expand into new therapeutic areas that demand scientific credibility and practical pathways for patients to receive treatment.